论文部分内容阅读
目的:探讨参脉注射液联合阿托伐他汀治疗冠心病慢性心力衰竭的临床疗效以及用药安全性,为该类疾病提供用药指导。方法:我院在2011年1月至2012年6月共住院治疗冠心病慢性心力衰竭患者90例,所有患者均给予常规治疗,将其随机分为3组,即Ⅰ组(n=30)采用参脉注射液治疗,Ⅱ组(n=30)采用阿托伐他汀治疗,Ⅲ组(n=30)采用参脉注射液联合阿托伐他汀治疗,对比分析3组患者的临床效果和不良反应。结果:Ⅰ组显效7例,有效9例,无效14例,总有效16例;Ⅱ组8例,有效8例,无效14例,总有效16例;Ⅲ组显效12例,有效17例,总有效29例;Ⅲ组的总有效例数要显著多于Ⅰ组和Ⅱ组,差异具有统计学意义(P<0.05);3组患者均有心悸、头晕、关节疼痛、血压下降、皮肤瘙痒等不良反应,但不良反应发生率差异不显著,不具有统计学意义(P>0.05)。结论:参脉注射液联合阿托伐他汀治疗冠心病慢性心力衰竭,具有良好的临床疗效,且不良反应发生率较低,具有较好的用药安全性,建议临床推广。
Objective: To investigate the clinical efficacy and safety of Shenmai injection combined with atorvastatin in the treatment of patients with chronic heart failure of coronary heart disease, and to provide guidance for the treatment of such diseases. Methods: From January 2011 to June 2012, 90 cases of chronic heart failure patients with coronary heart disease were treated in our hospital. All patients were given routine treatment. They were randomly divided into three groups (n = 30) The patients in group Ⅱ (n = 30) were treated with atorvastatin, while those in group Ⅲ (n = 30) were treated with Shenmai injection and atorvastatin. The clinical effects and adverse reactions in 3 groups were compared . Results: In group Ⅰ, 7 cases were markedly effective, 9 cases were effective, 14 cases were ineffective and 16 cases were effective. In group Ⅱ, 8 cases were effective, 8 cases were effective, 14 cases were ineffective and 16 cases were effective. Group Ⅲ was markedly effective in 12 cases and effective in 17 cases. Effective in 29 cases; the total effective number of group Ⅲ was significantly more than Ⅰ and Ⅱ, the difference was statistically significant (P <0.05); 3 groups of patients have palpitations, dizziness, joint pain, decreased blood pressure, pruritus, etc. Adverse reactions, but the incidence of adverse reactions was not significantly different, not statistically significant (P> 0.05). Conclusion: Shenmai injection combined with atorvastatin in the treatment of chronic heart failure of coronary heart disease has good clinical efficacy, and the incidence of adverse reactions is low, with good drug safety, it is recommended clinical promotion.